CEVLA

Ceva Santé Animale is a private, independent French animal health company focused on research, development, manufacturing, and commercialization of vaccines, pharmaceuticals, biopharmaceuticals, equipment, and services for companion animals and livestock. The company is one of the largest global animal health players and operates across companion animals, poultry, swine, and ruminants, with a strong emphasis on preventive medicine and vaccination. Ceva also has expanding biotechnology capabilities in pet therapeutics, including monoclonal antibodies and gene therapy, following its acquisition of Scout Bio in 2024. Its global footprint includes extensive R&D and manufacturing infrastructure, and the company positions itself around a One Health strategy linking animal, human, and environmental wellbeing.